Zacks Small-Cap Research
Sponsored – Impartial - Comprehensive

May 18, 2026
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com
101 N. Wacker Drive, Chicago, IL 60606

Abeona Therapeutics Inc.

(ABEO-NASDAQ)

ABEO: Three Patients Treated in 1Q26 with Two Additional QTCs Activated

Based on our probability adjusted DCF model that takes into account potential future revenues of pz-cel and selling a PRV, ABEO is valued at $14.00/share. This model is highly dependent upon the continued clinical and commercial success of pz-cel and will be adjusted accordingly based on future results.

Current Price (05/18/26)	$4.76
Valuation	**$14.00**

OUTLOOK

On May 13, 2026, Abeona Therapeutics, Inc. (ABEO) announced financial results for the first quarter of 2026 and provided a business update. The company reported that three patients were treated with Zevaskyn® during the first quarter of 2026, which translated into $8.7 million in net revenues. One patient has already been treated thus far in the second quarter of 2026, one patient has been biopsied, and an additional three patients' biopsies have been scheduled. The company recently brought two additional qualified treatment centers (QTCs) online, bringing the total to six. Abeona also announced the in-licensing of a novel engineered T cell therapy targeting prostate-specific membrane antigen (PSMA), with plans to enter the clinic in 2027.

SUMMARY DATA

52-Week High	**$7.23**
52-Week Low	**$4.17**
One-Year Return (%)	**-7.75**
Beta	**1.13**
Average Daily Volume (sh)	**1,294,924**
Shares Outstanding (mil)	**54**
Market Capitalization ($mil)	**$258**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**81**
Insider Ownership (%)	**7**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2026 Estimate	**3.4**
P/E using 2027 Estimate	**34.8**

Risk Level	**Average**
Type of Stock	**Small-Value**
Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2025	0.0 A	0.4 A	0.0 A	5.4 A	5.8 A
2026	8.7 A	10.8 E	16.2 E	19.3 E	55.0 E
2027					94.6 E
2028					146.8 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2025	-$0.24 A	$2.07 A	-$0.10 A	-$0.37 A	$1.34 A
2026	-$0.30 A	-$0.25 E	-$0.20 E	-$0.18 E	-$0.94 E
2027					-$0.76 E
2028					-$0.96 E

WHAT'S NEW

Business Update

Three Patients Treated in 1Q26, Seven Patients In-queue

Abeona Therapeutics, Inc. (ABEO) is continuing the commercial launch of Zevaskyn®, with three patients treated in the first quarter of 2026 and one patient treated, one patient biopsied, three patients scheduled to be biopsied, and three more patients with biopsies in progress in the second quarter of 2026. Thus far, more than 100 patients have been identified through qualified treatment center (QTC) and non-QTC physicians and those patients are in the process of being referred. The three patients treated in the first quarter of 2026 were covered by commercial payers, while the one patient treated in the fourth quarter of 2025 was covered by Medicaid. Approximately 95% of commercially insured lives in the U.S. are now covered by published policies and there have been no final payer denials or patient attrition thus far.

In April and May 2026, Abeona announced the activation of two new QTCs at New York-Presbyterian/Columbia University Irving Medical Center in New York City and Children's Hospital of Philadelphia. The company now has six QTCs active across the U.S. as shown in the following figure.



Source: Abeona Therapeutics, Inc.

In-licenses Novel T Cell Therapy Technology

Abeona recently announced the in-licensing of ABO-701, a novel engineered T cell therapy that targets Prostate-Specific Membrane Antigen (PSMA), a validated target for advanced prostate cancer, which is responsible for >30,000 cancer deaths in the U.S. each year.

ABO-701 is based on the Synthetic Immune Receptor (SIR-T) technology, which combines the best features of chimeric antigen receptor (CAR-T) and T Cell Receptors (TCR). The following slide shows how a SIR uses an antibody binding domain for target engagement along with the same co-stimulatory molecules found in a TCR. This allows for SIRs to be designed to a tumor associated antigen while retaining the physiological regulation of a TCR.



Source: Abeona Therapeutics, Inc.

The preclinical results for PSMA SIR-T™ are very encouraging, as the product shows better tumor remission and durability compared to CAR-T controls with the same PSMA binding domain. The images on the left show tumor growth in mice, with all mice treated with PSMA SIR-T showing complete tumor regression, which led to 100% of mice surviving the experiment compared to less than 50% for any of the other treatment groups. For a full overview of the SIR technology and the preclinical data that has been generated thus far, investors should view the presentation by the inventor of the SIR technology Dr. Preet M. Chaudhary.



Source: Abeona Therapeutics, Inc.

Abeona is planning to file an Investigational New Drug (IND) application and commence first-in-human studies with ABO-701 in the second half of 2027. In addition to prioritizing ABO-701, the company has deprioritized its ophthalmology programs.

Financial Update

On May 13, 2026, Abeona announced financial results for the first quarter of 2026. The company reported net product revenue of $8.7 million, which represented a quarter-over-quarter increase of $6.3 million compared to $2.4 million in the fourth quarter of 2025. Cost of sales for the first quarter of 2026 were $2.7 million, which was a quarter-over-quarter increase in cost of sales of $1.7 million compared to $1.0 million in the fourth quarter of 2025. R&D expenses in the first quarter of 2026 were $9.6 million compared to $9.9 million for the first quarter of 2025. The increase included a single up-front payment of $7.0 million for in-licensing of the PSMA-SIR-T asset. Without that transaction, R&D spending decreased by $7.4 million. The reduction was primarily due to costs capitalized into inventory and engineering runs and other production costs that are no longer considered research and development. SG&A costs in the first quarter of 2026 were $19.5 million compared to $9.8 million for the first quarter of 2025. The increase was primarily due to the company's commercial transition that included $5.4 million in personnel and stock-based compensation, $1.9 million of certain engineering and training expenses previously classified as R&D that were transitioned to SG&A, and the remainder due to other commercial costs related to Zevaskyn.

Abeona exited the first quarter of 2026 with approximately $168.3 million. As of May 8, 2026, the company had approximately 57.0 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 71.0 million.

Conclusion

The commercial launch of Zevaskyn is proceeding well, and in the current quarter Abeona announced that one patient has been treated, one patient has been biopsied, and six patients either have a biopsy scheduled or scheduling is in progress. The company has achieved 95% coverage of commercial lives in the U.S. and there have been no issues thus far with payer denials. The SIR-T technology looks very interesting, which includes preclinical data showing complete tumor regression using the PSMA SIR-T product. Thus, we will be monitoring the development of ABO-701 very closely as the company works to advance the product into clinical testing in 2027. We have added ABO-701 to our model, and while the product is likely at least seven years away from approval, a successful prostate cancer therapy would likely generate multi-billion-dollar peak revenues. Our valuation is now $14 per share.

PROJECTED FINANCIALS

Abeona Therapeutics Inc.	2025 A	Q1 A	Q2 E	Q3 E	Q4 E	2026 E	2027 E	2028 E
ZEVASKYN™	$2.4	$8.7	$10.8	$16.2	$19.3	$55.0	$94.6	$146.8
License and other revenues	$3.4	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Revenues	**$5.8**	**$8.7**	**$10.8**	**$16.2**	**$19.3**	**$55.0**	**$94.6**	**$146.8**
Cost of revenues	$1.5	$2.7	$3.2	$4.7	$5.8	$16.4	$28.0	$42.0
Gross Margin	*74%*	*69%*	*70%*	*71%*	*70%*	*70%*	*70%*	*71%*
Royalties	$1.9	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Research & development	$26.8	$9.6	$4.0	$4.0	$4.0	$21.6	$22.0	$24.0
General & administrative	$65.0	$19.5	$20.0	$21.0	$22.0	$82.5	$85.0	$90.0
Operating Income	($89.4)	($23.0)	($16.4)	($13.5)	($12.5)	($65.5)	($40.4)	($9.2)
Operating Margin	*-1536.9%*	*-264.1%*	*-151.9%*	*-83.5%*	*-64.8%*	*-119.0%*	*-42.7%*	*-6.3%*
Non-Operating Expenses (Net)	$160.7	$6.0	$2.0	$2.0	$2.0	$12.0	$0.0	$1.0
Pre-Tax Income	$71.3	($17.1)	($14.4)	($11.5)	($10.5)	($53.5)	($40.4)	($8.2)
Income Taxes	$0.1	$0.0	$0.0	$0.0	$0.0	$0.0	$5.4	$20.0
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*-13%*	*-244%*
Net Income	**$71.2**	**($17.1)**	**($14.4)**	**($11.5)**	**($10.5)**	**($53.5)**	**($45.8)**	**($28.2)**
Net Margin	*1223.1%*	*-*	*-*	*-*	*-*	*-*	*-48.4%*	*-19.2%*
Reported EPS	**$1.34**	**($0.30)**	**($0.25)**	**($0.20)**	**($0.18)**	**($0.94)**	**($0.76)**	**($0.46)**
Basic Shares Outstanding	53.0	56.6	57.0	57.0	57.0	56.9	60.0	61.0

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.